Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-06-23 am EDT
217.30 SEK   +0.05%
06/10Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress
CI
06/08Sobi, Apellis Start Dosing Patients in Late-Stage Trial of Rare Kidney Disease Treatment
MT
06/07Sobi, Apellis Dose First Patient In Phase 3 Study Of Pegcetacoplan For Rare Kidney Diseases
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/17/2022 06/20/2022 06/21/2022 06/22/2022 06/23/2022 Date
211.1(c) 213.6(c) 214.9(c) 217.2(c) 217.3(c) Last
1 452 892 231 482 789 722 672 890 362 533 Volume
+2.03% +1.18% +0.61% +1.07% +0.05% Change
More quotes
Estimated financial data (e)
Sales 2022 17 499 M 1 728 M 1 728 M
Net income 2022 2 342 M 231 M 231 M
Net Debt 2022 6 507 M 643 M 643 M
P/E ratio 2022 28,1x
Yield 2022 -
Sales 2023 18 710 M 1 848 M 1 848 M
Net income 2023 3 285 M 324 M 324 M
Net Debt 2023 2 124 M 210 M 210 M
P/E ratio 2023 19,6x
Yield 2023 -
Capitalization 64 137 M 6 334 M 6 334 M
EV / Sales 2022 4,04x
EV / Sales 2023 3,54x
Nbr of Employees 1 569
Free-Float 57,8%
More Financials
Company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the... 
Read more
Sector
Pharmaceuticals
Calendar
07/19 | 02:00amEarnings Release
More about the company
Ratings of Swedish Orphan Biovitrum AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
06/10Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Effica..
CI
06/08Sobi, Apellis Start Dosing Patients in Late-Stage Trial of Rare Kidney Disease Treatmen..
MT
06/07Sobi, Apellis Dose First Patient In Phase 3 Study Of Pegcetacoplan For Rare Kidney Dise..
MT
06/07Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT..
CI
06/01Swedish Orphan Biovitrum, Sanofi Secure US FDA's Breakthrough Therapy Designation For H..
MT
06/01FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A
AQ
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
05/10Swedish Orphan Biovitrum AB Elects Bo Jesper Hansen as New Board Member
CI
04/28Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March ..
CI
04/28TRANSCRIPT : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Swedish Drugmaker Sobi Confirms FY22 Revenue Outlook After Q1 Growth
MT
04/28Drugmaker Sobi books profit fall on restructuring, Russia
RE
04/28Sobi publishes Q1 2022 report
AQ
04/28Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Year 2022
CI
04/20INVITATION : Sobi's Q1 2022 report
AQ
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
06/10Apellis Pharmaceuticals, Inc. et Sobi(R) présentent de nouvelles données renforçant le ..
06/08Sobi et Apellis commencent à doser les patients dans le cadre d'un essai de stade avanc..
06/07Sobi et Apellis administrent une dose au premier patient de l'étude de phase 3 du pegce..
06/07Apellis Pharmaceuticals, Inc. et Sobi annoncent que le premier patient a reçu une dose ..
06/01POINT SUR LES FORTES VARIATIONS DU J : les investisseurs ont trouvé Doc Martens à leurs pi..
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 217,30 SEK
Average target price 245,38 SEK
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Christine Wesström Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)17.40%6 334
CSL LIMITED-6.70%90 814
SAMSUNG BIOLOGICS CO.,LTD.-7.97%45 825
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 498
BIOGEN INC.-11.67%31 038
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.19%24 084